Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

Podobné jednotky

• The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
  Autor: Bai, Hao, a další
  Vydáno: (2017)
• Afatinib: new treatment options for lung cancer with activating EGFR mutations
  Autor: M. V. Stepanchenko, a další
  Vydáno: (2015-12-01)
• Treatment of EGFR mutation–positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report
  Autor: Nonagase, Yoshikane, a další
  Vydáno: (2018)
• Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
  Autor: Kanemura, Hiroaki, a další
  Vydáno: (2020)
• Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
  Autor: Llinás-Quintero, Néstor, a další
  Vydáno: (2019)